NCT05897788 Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
| NCT ID | NCT05897788 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Opioid Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,808 participants |
| Start Date | 2024-03-20 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,808 participants in total. It began in 2024-03-20 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is growing recognition of the need for approaches to initiate treatment wherever patients touch the health care system, including the Emergency Department (ED). Most research has focused on initiation of medications for opioid use disorder (MOUDs) in the ED rather than ensuring continued treatment post-discharge. The investigators propose to adapt evidence-based interventions to support patients' complex needs and facilitate continued treatment, rather than discharging them and having them navigate outpatient treatment systems with limited support. The research team will randomize participants into 1 of 4 arms to receive varying degrees of augmented usual care, including daily check-ins and contingency management. The investigators plan to examine the effects of check-ins and contingency management on engagement with addiction treatment and equity of treatment effects among racial and ethnic subgroups and assess important moderators of treatment effects.
Eligibility Criteria
Inclusion Criteria: * Participants must be 18 or older * Screen positive for OUD * Bridge buprenorphine prescription (emergency department (ED) enrollment - Buprenorphine prescription at ED discharge; Bridge clinic enrollment - new buprenorphine prescription associated with on-demand or drop-in encounter * English reading ability * Have a mobile phone capable of receiving text messages Exclusion Criteria: * Not being up to date with requirements above
Contact & Investigator
Kit Delgado, MD, MS
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT05897788 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Opioid Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05897788 currently recruiting?
Yes, NCT05897788 is actively recruiting participants. Contact the research team at arielle.berk@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05897788 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05897788 clinical trial?
NCT05897788 is sponsored by University of Pennsylvania. The principal investigator is Kit Delgado, MD, MS at University of Pennsylvania. The trial plans to enroll 1,808 participants.